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Abstract—The newly synthesized linoleic acid derivative, FR236924, induces a long-lasting facilitation of hippocampal neuro-
transmission based on a persistent enhancement in the activity of presynaptic nicotinic ACh receptors via a PKC pathway and the
ensuing increase in glutamate release, not only in vitro but in vivo at a low dosage (2mg/kg, ip), which suggested the possibility of
its use as a promising anti-dementia drug.
# 2003 Elsevier Science Ltd. All rights reserved.
Essential fatty acids, such as arachidonic acid (1), lino-
leic acid (2), and linolenic acid (3) have long been
thought to play important roles as raw materials for
bioactive lipid mediators such as prostaglandins and/or
leukotrienes. Therefore, few attempts to obtain syn-
thetic essential fatty acid derivatives have been descri-
bed by medicinal chemists. In recent years however,
interesting biological activity themselves has been found
in many areas, for example, activation of protein kinase
C1 and peroxisome proliferator-activated receptors.2
We found earlier that arachidonic acid (1), a cis-unsa-
turated free fatty acid, persistently enhances the activity
of nicotinic acetylcholine (ACh) receptors via a protein
kinase C (PKC) pathway.35 The action of arachidonic
acid on presynaptic nicotinic ACh receptors caused a
marked increase in the release of the excitatory neuro-
transmitter glutamate, thereby leading to a long-lasting
facilitation of hippocampal synaptic transmission, that
resembles long-term potentiation (LTP), a cellular
model of learning and memory.5,6 A similar effect was
also obtained with other cis-unsaturated free fatty acids,
such as oleic, linoleic, and linolenic acid.7,8 It is sug-
gested from these results that cis-unsaturated free fatty
acids could enhance cognitive function. Additionally,
the effect of arachidonic acid on nicotinic ACh recep-
tors was not inhibited by a lipoxygenase inhibitor or a
cyclooxygenase inhibitor, suggesting that arachidonic
acid itself, and not its bioactive metabolites such as
prostaglandins and/or leukotrienes, potentiates nico-
tinic ACh receptor activity.5 It is of major interest to
know whether cis-unsaturated free fatty acids exert their
actions in in vivo systems, since the free fatty acids can
be promptly metabolized to generate the multi-bioactive
metabolites and are thus decomposed. This prompted
the present study to design FR236924 (4), a linoleic acid
derivative without the double bonds, since they are
known to be the key moieties in metabolic reactions in
vivo, and to assess whether the compound exhibits
activities similar to the original free fatty acids or not.
The results of the present study demonstrate that
FR236924 persistently potentiates nicotinic ACh recep-
tor responses via a PKC pathway and induces an ‘LTP-
like’ long-lasting facilitation of hippocampal neuro-
transmission. This suggests the possibility of use of
FR236924 as a promising anti-dementia drug. Herein,
we describe the design, synthesis, and biological activity
of FR236924.
Design of FR236924
Our focus was to design compounds replacing the cis-
double bonds by other biologically stable bioisosteres
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because of the reasons described above, and synthesized
compounds bearing cyclopropane rings instead of the
cis-double bonds9 because of structurally similarity
(Fig. 1).
We initially screened the compounds for enhancing
action on nicotinic ACh receptor responses, using Tor-
pedo nicotinic ACh receptors expressed in Xenopus
oocytes (Table 1). Among the compounds examined,
linoleic acid derivative (4, FR236924) and the oleic acid
derivative (8) enhanced Torpedo nicotinic ACh receptor
responses, with compound 4 showing the greater
response. In contrast, the arachidonic acid derivative (5)
and the linolenic acid derivative (6), inhibited the
responses, whereas arachidonic acid and linolenic acid
potentiated the Torpedo nicotinic ACh receptor
response.3,4,8 The mechanism underlying this inhibitory
action of compounds 5 and 6 is presently unknown.
The synthesis of the cyclopropane derivatives used in
this study is shown in Figure 2. Cyclomethylation onto
the cis-double bond was carried out using diethylzinc
and diiodomethane in dichloromethane and resulted in
cis-cyclopropane derivatives as a mixture of diaster-
eomers. Ester hydrolysis with 1N LiOH at 60 C in
dioxane gave the desired compounds. After purification
by chromatography on silica gel, they were used in the
biological experiments.10
Biological Results and Discussion on FR236924
Of the neuronal nicotinic ACh receptor subunits cloned,
a7 and a4b2 receptors are predominantly expressed in
the brain.1115 a7 receptors are preferentially localized
on presynaptic terminals and stimulate the release of the
excitatory neurotransmitter glutamate in the hippo-
campus.16,17 To examine the effect of FR236924 on
neuronal nicotinic ACh receptors, a7 receptors were
expressed in Xenopus oocytes. FR236924 (10 mM)
induced a gradually-developing and persistent potentia-
tion of a7 receptor responses, reaching 14415% of
original amplitude 25min after treatment (Fig. 3A). The
effect was inhibited by the selective PKC inhibitor,
GF109203X (100 nM), suggesting that like linoleic
acid,8 FR236924 potentiates nicotinic ACh receptor
responses via a PKC pathway (Fig. 3B).
If FR236924 persistently enhances a7 receptor activity,
then it could facilitate hippocampal neurotransmission
by enhancing presynaptic glutamate release. To address
this point, we monitored population spikes (PSs) in the
dentate gyrus of rat hippocampal slices. As expected,
FR236924 facilitated hippocampal neurotransmission in
a bell-shaped dose-dependent manner at concentrations
ranging from 10 nM to 10 mM (Fig. 3C). The compound
sustained the facilitation more than 60min after 10-min
treatment. The maximal effect was obtained with 100 nM
FR236924, and the potentiation reached 2276% of
basal PS amplitude 60min after treatment (Fig. 3C). The
facilitatory action was inhibited by a-bungarotoxin
Figure 1. Structural similarity between linoleic acid and FR236924 (4).
(a) A molecular mechanics (MM) structure of 4 [(9S, 10R, 12R, 13S)-
FR236924 was presented in this figure. Similar results were obtained
on study of the other three isomers], (b) that of linoleic acid, and (c) a
superimposed structure of 4, and linoleic acid. Structure of linoleic
acid was obtained by the Maximin2 force field of SYBYL version 6.7
using a linear conformation as the starting structure, and was thought
to be a one of its local minimum structure (no conformation search
study was performed). Structure of 4 was obtained in the way that that
of 4 was superimposed on the linoleic acid structure using MULTIFIT
function of SYBYL version 6.7.
Table 1. The effect of cis-unsaturated free fatty acids and their deri-
vatives (10mM) on Torpedo nicotinic ACh receptor responses
Structure Ach receptor responses










Figure 2. Synthesis of cyclopropane derivatives. Reagents and condi-
tions: (a) Et2Zn, CH2I2/CH2Cl2,5 to 0 C, (b) 1NLiOH/dioxane, 60 C.
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(50 nM), an inhibitor of a7 receptors (Fig. 3D). Taken
together, FR236924 appears to induce an ‘LTP-like’ long-
lasting facilitation of hippocampal neurotransmission by
enhancing nicotinic ACh receptor activity.
To finally examine the in vivo effect of FR236924, we
monitored PSs in the dentate gyrus of the intact rat
hippocampus. Before this examination, we measured
the concentration of FR236924 in blood after ip and po
administration.18 FR236924 was detected in blood at
more than 0.5 mg/mL (1.8 mM), that is 180 times
greater than that of the maximum effective concen-
tration (100 nM). These results raised our hopes that ip
administration of FR236924 would be effective in intact
rat, as well as in the in vitro study.
As expected, FR236924 (2mg/kg, 6 mM, ip) facilitated
hippocampal neurotransmission, the effect being evident
120min after injection (18615% of basal PS ampli-
tude) (Fig. 4). This would imply that the stable facilitatory
action of FR235924 on hippocampal neurotransmission is
still obtained with the in vivo system.
Neuronal nicotinic ACh receptors as well as muscarinic
ACh receptors are constituted of the cholinergic sys-
tems, and are rich in the limbic systems including the
hippocampus, a center of cognitive function.19 A con-
sistent finding is that cholinergic systems are disrupted
in the Alzheimer brain.2022 In addition, the number of
nicotinic ACh receptors decreases in the aging brain.23
Nicotinic ACh receptors, thus, are likely to play a sig-
nificant role in cognitive functions. We earlier found
that perforant path LTP and Schaffer-collateral LTP,
Figure 3. (A, B) Effect of FR236924 on whole-cell membrane currents through a7 receptor channels. (C, D) Effect of FR236924 on PSs in rat
hippocampal slices. (A) ACh (100mM) was applied to an oocyte before and after 5-min treatment with FR236924 (10mM) with 5-min intervals. (B)
ACh (100 mM) was applied to an oocyte before and after 5-min treatment with FR236924 (10mM) with 5-min intervals in the presence of
GF109203X (100 nM). The holding potential was 60mV. (C) PSs were monitored from the granular cell layer of rat hippocampal slices before and
after 10-min treatment with FR236924 at the concentrations indicated. (D) PSs were recorded before and after 10-min treatment with FR236924
(100 nM) in the presence of a-bungarotoxin (50 nM).
Figure 4. Effect of FR236924 on PSs in the intact rat hippocampus.
PSs were recorded before and after injection with FR236924 (2mg/kg,
ip). In the graph, each point represents the mean (SEM) percent of
basal PS amplitude (0min) (n=6). Illustrated PSs were recorded 0 and
120min after injection with FR236924.
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which express in an N-methyl-d-aspartate (NMDA)
receptor-dependent manner,24,25 were induced by acti-
vating nicotinic ACh receptors, independently of
NMDA receptors.26 This suggests that nicotinic ACh
receptors are a downstream target of the NMDA
receptor signal in the expression of LTPs.26
An important question is: what signal is involved in the
LTPs? The answer may be that cis-unsaturated free
fatty acids may mediate it. High frequency stimulation
to induce LTP causes a huge increase in the release of
glutamate followed by high activation of NMDA
receptors, thereby producing cis-unsaturated free fatty
acids, such as arachidonic, oleic, linoleic, and linolenic
acid, which in turn, persistently enhance presynaptic
nicotinic ACh receptors, leading to a long-lasting facil-
itation of hippocampal synaptic transmission.5,6 Cis-
unsaturated free fatty acids, therefore, may serve as
retrograde messengers in NMDA receptor-dependent
LTP. This raises the possibility that compounds target-
ing nicotinic ACh receptors, like cis-unsaturated free
fatty acids, can enhance learning and memory; that is,
amelioration of dementia, such as Alzheimer disease
and senile memory deficits. In the present study,
FR236924, a linoleic acid derivative without unstable
cis-double bonds, induced an ‘LTP-like’ long-lasting
facilitation of hippocampal neurotransmission in both
in vitro and in vivo systems by targeting nicotinic ACh
receptors. This gives us hope that FR236924 could be a
novel and promising drug against a variety of forms of
dementia. Further pharmacological and physiological
studies on FR236924 in vitro and in vivo will be reported
in the future.
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